

LITERATURA

1. Ferlay J, Ervik M, Lam F et al. Global Cancer Observatory: Cancer Today (2024). (cit. 2024-10-08). Lyon, France: International Agency for Research on Cancer. (online). Available from: <https://gco.iarc.who.int/today>.
2. Krejčí D, Mužík J, Šnábl I, Gregor J, Komenda M, Dušek L. Portál epidemiologie novotvarů v ČR (online). Masarykova univerzita, Brno, 2024. (cit. 2025-07-07). Available from: <https://www.svod.cz>. Verze 8.0.1
3. Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. *Gastroenterology*. 2020;159(1):335-49.e15.
4. Rubin G, Walter F, Emery J, et al. Reimagining the diagnostic pathway for gastrointestinal cancer. *Nat Rev Gastroenterol Hepatol*. 2018;15(3):181-8.
5. GBD 2017 Colorectal Cancer Collaborators. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol*. 2019;4(12):913-33.
6. Suchanek S, Grega T, Ngo O, et al. How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia? *World J Gastroenterol*. 2016;22(36):8103-11.
7. McNabb S, Harrison TA, Albanes D, et al. Meta-analysis of 16 studies of the association of alcohol with colorectal cancer. *Int J Cancer*. 2020;146(3):861-873.
8. NICE. Behaviour change: individual approaches. Public health guideline (PH49). 2014. Available from: <https://www.nice.org.uk/guidance/ph49>.
9. Loomans-Kropp HA, Umar A. Increasing incidence of colorectal cancer in young adults. *J Cancer Epidemiol*. 2019;2019:9841295.
10. Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974–2013. *J Natl Cancer Inst*. 2017;109(8):djw322.
11. van Leerdam ME, Roos VH, van Hooft JE, et al. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy*. 2019;51(11):1082-1093.
12. Wilkinson AN, Lieberman D, Leontiadis GI, et al. Colorectal cancer screening for patients with a family history of colorectal cancer or adenomas. *Can Fam Physician*. 2019;65(11):784-789.
13. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. *Gastroenterology*. 2015;148(3):639-51.e28.
14. Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. *Lancet*. 2020 Jan 11;395(10218):123-131.
15. Wijnands AM, de Jong ME, Lutgens MWMD, et al. Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis. *Gastroenterology*. 2021 Apr;160(5):1584-1598.
16. Sato Y, Tsujinaka S, Miura T, et al. Inflammatory Bowel Disease and Colorectal Cancer: Epidemiology, Etiology, Surveillance, and Management. *Cancers (Basel)*. 2023;15(16):4154.
17. Suchanek Š. Screening kolorektálního karcinomu v České republice v roce 2022. *Gastroent Hepatol* 2022;76(5):371.
18. Bretthauer M, Løberg M, Wieszczy P, et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. *N Engl J Med*. 2022;387(17):1547-1556.
19. Dominitz JA, Robertson DJ, Ahnen DJ, et al. Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design. *Am J Gastroenterol*. 2017;112(11):1736-1746.
20. Sekiguchi M, Westerberg M, Ekblom A, et al. Detection rates of colorectal neoplasia during colonoscopies and their associated factors in the SCREESCO study. *J Gastroenterol Hepatol*. 2022;37(11):2120-2130.
21. Castells A, Quintero E, Bujanda L, et al. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. *Lancet*. 2025;405(10486):1231-1239.
22. Medina-Lara A, Grigore B, Lewis R, et al. Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis. *Health Technol Assess*. 2020;24(66):1-332.
23. Ngo O, Hejzmanová K, Suchanek Š, et al. Coverage by examinations associated with early detection of colorectal neoplasia in the Czech Republic. *Eur J Public Health*. 2023;33(3):515-521.
24. Quinn L, Bird P, Remsing S, Reeves K, Lilford R. Unintended consequences of the 18-week referral to treatment standard in NHS England: a threshold analysis. *BMJ Qual Saf*. 2023;32(12):712-720.
25. Lauby-Secretan B, Vilahur N, Bianchini F, Guha N, Straif K. The IARC perspective on colorectal cancer screening. *New England Journal of Medicine*. 2018 May 3;378(18):1734-40.
26. Zaval M, Suchanek S, Majek O, et al. Colorectal cancer screening: 20 years of development and recent progress. *World J Gastroenterol*. 2014;20(14):3825-34.
27. Ponti A, Anttila A, Ronco G et al. Cancer Screening in the European Union (2017). Report of the Implementation of the Council Recommendation on Cancer Screening; 2017. Available from: https://health.ec.europa.eu/system/files/2017-05/2017_cancerscreening_2ndreportimplementation_en_0.pdf.

Další literatura u autora
a na www.medicinapopraxi.cz.

Quick MASTER

analyzer

TESTOVÁNO

Klinickou laboratoří
Oblastní nemocnice Kladno a.s.

Ing. Luděk Šprongl
primář klinické laboratoře

Multifunkční POCT s nejžádanějšími parametry

➤ **CRP**

➤ **Strep A**

➤ **FOB**

➤ **HbA1c**

➤ **Mikroalbumin**

➤ **PSA***

novinka

hs-Troponin I

➤ **Troponin T**

➤ **D-dimer**

➤ **NT-proBNP**

➤ **Vitamín D**

➤ **SARS-CoV-2 Ag**

Nová referenční mez <40ng/l

Změna měřicího rozsahu 10-15000ng/l

Nová referenční mez <50ng/l

Změna měřicího rozsahu 30-10000ng/l

**vylepšení
testů**

*ve vývoji



QuickSeal

info@quickseal.eu
+420 273 167 580

www.quickseal.eu
f QuickSealczech